Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kevin Almerico

Pulmonary Disease Miami, FL Medical Doctor

NPI 1619339769 CMS profile 4221863

7000 Sw 97Th Ave Ste 120, Miami, FL 33173

Open in the dashboard

General payments

$8,335

306 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Almerico of Miami, FL is reported in the CMS Open Payments database as having received $8,335 across 306 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,583 132
2024 General $3,026 118
2023 General $1,627 54
2022 General $85 1
2021 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Almerico
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Kevin Almerico were reported at $3,583. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Kevin Almerico Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $13 $269 $68–$1,072 $132
2022 $85 $390 $100–$1,457 $149
2023 $1,627 $419 $114–$1,659 $160
2024 $3,026 $476 $123–$1,818 $164
2025 $3,583 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,848 60 payments
  2. United Therapeutics Corporation $690 19 payments
  3. AstraZeneca Pharmaceuticals LP $664 30 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $517 20 payments
  5. Baxter Healthcare $415 19 payments
  6. Electromed, Inc. $404 19 payments
  7. Genzyme Corporation $373 17 payments
  8. Insmed, Inc. $365 14 payments
  9. Regeneron Healthcare Solutions, Inc. $333 10 payments
  10. Amgen Inc. $328 18 payments
  11. Other $2,397 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,217 304 payments
  2. Education $98 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $20 1 payment
Products named General payments · program years 2021–2025
  1. NUCALA $1,223 35 payments
  2. TRELEGY ELLIPTA $500 24 payments
  3. DUPIXENT $471 18 payments
  4. TYVASO $412 12 payments
  5. SMARTVEST $404 19 payments
  6. Arikayce $365 14 payments
  7. OFEV $347 12 payments
  8. TEZSPIRE $328 18 payments
  9. ACTHAR $312 10 payments
  10. Hillrom - Vest System Model 105 Home Care $310 14 payments
  11. Other $3,857 145 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

737

Median for Pulmonary Disease: 936

Drug cost

$180,863

Median for Pulmonary Disease: $487,987

Branded share of claims

85.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 91 $59,553
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 66 $43,465
Breo Ellipta Fluticasone/Vilanterol Brand 73 $31,037
Eliquis Apixaban Brand 16 $9,425
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 14 $6,643
Albuterol Sulfate Hfa Albuterol Sulfate Brand 221 $6,364
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 11 $5,620
Symbicort Budesonide/Formoterol Fumarate Brand 22 $5,024
Breyna Budesonide/Formoterol Fumarate Brand 27 $4,067
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 15 $3,137

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$173,904

Medicare's payments for the services billed

Medicare patients

476

Average age 78

Services billed

2,166

248 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
COPD 61%
Arthritis 58%
Heart failure 52%
Diabetes 51%
Chronic kidney disease 49%
Atrial fibrillation 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $350
$350 — —
DUPIXENT
  • GENZYME CORPORATION $186
  • Regeneron Healthcare Solutions, Inc. $58
$244 — —
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $228
$228 — —
YUPELRI
  • Mylan Specialty L.P. $228
$228 — —
Arikayce
  • Insmed, Inc. $198
$198 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

306 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record